Q-omics provides the consensus-scored GRK1 profile across patient tissues and cancer cell-line models. GRK1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GRK1 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, GRK1 RNA expression shows 13,223 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, THCA, and THYM as cancer lineages where GRK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRK1 survival associations across molecular data types. GRK1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRK1 RNA expression–survival associations across cancer types. High GRK1 expression shows unfavorable associations in LIHC, LUSC, BLCA, ACC and UCEC, but favorable associations in LAML. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GRK1 RNA expression.
This table summarizes GRK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GRK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRK1 shows lower tumor expression in THCA, KIRC, KIRP and PRAD and higher tumor expression in COAD and BRCA. The THCA box plot shows higher GRK1 RNA expression in normal versus tumor tissue (log2 FC = −0.892, t-test p < 0.001).
This table shows molecular features associated with GRK1 in patient tissues and cancer cell lines. In patient samples, GRK1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
